

1       **The potential of different molecular biology methods in tracking clones of**  
2                                    ***Acinetobacter baumannii* in an ICU setting.**

3  
4       **Nithin Sam Ravi<sup>1</sup>, Shalini Anandan<sup>1</sup>, Saranya Vijayakumar<sup>1</sup>, Radha Gopi<sup>1</sup>, Bruno S. Lopes<sup>2\*</sup>,**  
5                                    **Balaji Veeraraghavan<sup>1\*</sup>**

6                   <sup>1</sup>Department of Clinical Microbiology, Christian Medical College, Vellore

7                   <sup>2</sup>School of Medicine, Medical Sciences and Nutrition, Medical Microbiology,  
8                                    University of Aberdeen, UK.

9  
10       **Running Title:** Molecular methods in tracking clones of *A. baumannii*

11  
12  
13  
14  
15  
16       **\*Correspondence**

17       Dr. V. Balaji, Professor and Head, Department of Clinical Microbiology, Christian Medical  
18       College, Vellore – 632 004, Tamil Nadu, India. E-mail: [vbajaji@cmcvellore.ac.in](mailto:vbajaji@cmcvellore.ac.in)

19       Dr Bruno S. Lopes, School of Medicine, Medical Sciences and Nutrition, Medical  
20       Microbiology. 0:025 Polwarth Building. Aberdeen. AB25 2ZD. E-mail:  
21       [bruno.lopes@abdn.ac.uk](mailto:bruno.lopes@abdn.ac.uk)

22

23

24 **Abstract (248 words)**

25 **Purpose:** This study aimed at characterising *A. baumannii* strains isolated from patients in  
26 ICU setting using molecular techniques to study clonal relatedness to determine a fast,  
27 efficient and a cost effective way of detecting persistent clones.

28 **Methodology:** *A. baumannii* (n=17) were obtained in June and November 2015 from a single  
29 ICU setting in South India. DNA typing methods such as MLST, SBT and DNA fingerprinting  
30 PCRs (M13, DAF4, ERIC2) were employed to understand the association of clones. PCR for  
31 antimicrobial resistance genes *ISAbal-bla<sub>OXA-51-like</sub>*, *ISAbal-bla<sub>OXA-23-like</sub>*, *bla<sub>NDM-1</sub>*, *bla<sub>PER-7</sub>*,  
32 *bla<sub>TEM-1</sub>* and virulence genes *cpa 1*, *cpa 2* and *pkf* were performed.

33 **Results:** The MLST showed some degree of corroboration with other DNA typing methods  
34 such as SBT and M13, DAF4, ERIC2. M13 PCR was found to give better results than other  
35 fingerprinting methods. ST848 (CC92) was the dominant strain isolated in both June and  
36 November. All isolates were *bla<sub>OXA-51-like</sub>* positive with 16 having *ISAbal* upstream of *bla<sub>OXA-</sub>*  
37 *51-like* and *bla<sub>OXA-23-like</sub>* genes. Genes such as *bla<sub>NDM-1</sub>* (23%, n= 4), *bla<sub>PER-7</sub>* (58.8%, n= 10), *pkf*  
38 (82%, n= 14), *bla<sub>TEM-1</sub>* (5.8%, n=1), *cpa 1* (5.8%, n=1) and *cpa 2* (5.8%, n=1) were also  
39 detected.

40 **Conclusion:** M13 PCR can be used in routine environmental surveillance for detection of  
41 persistent antibiotic resistant clones in an ICU setting because of its reliability and simplicity.  
42 Further studies based on greater sample size, conducted at multi-centre level can give a  
43 better understanding on the reliability of molecular methods which can be used for  
44 detection of persistent clones in hospital setting.

46 **Introduction:**

47 Nosocomial infections are a major problem for immunocompromised patients, increasing  
48 mortality and morbidity rates, even in a specialized and well-equipped hospital  
49 environment. The main cause of nosocomial infections is bacterial drug resistance to various  
50 antimicrobial agents and the difficulty in eradicating them. *Acinetobacter baumannii* is an  
51 opportunistic pathogen of clinical significance which causes various hospital and  
52 community-acquired infections such as pneumonia, urinary tract infection, suppurative  
53 infection and bloodstream infections [1]. It is not only emerging as a cause of numerous  
54 global outbreaks but also has increasingly high rates of resistance which makes treatment  
55 difficult for severely ill patients that need hospitalisation [2–4]. The frequency by which the  
56 intubated patient acquires *A. baumannii* infection is around 58% compared to 30% which is  
57 caused by other Gram-negative bacteria [5].

58 The most important mechanisms through which *A. baumannii* can acquire resistance are:  
59 presence of intrinsic antimicrobial resistance (AMR) genes such as oxacillinases, insertion  
60 sequences like *ISAb<sub>a</sub>1* which help in mobilisation of such genes and control their [6, 7].  
61 Virulence genes such as serine protease (*pkf*) which degrades the essential complement  
62 components like C3 and endopeptidases (*cpa1* and *cpa2*) which disrupt the common  
63 mechanism of coagulation, help the organism to prevail and disseminate in the hospital  
64 setting [8, 9]. Resistance Nodulation Division (RND) family efflux pumps genes such as  
65 *adeABC*, *adeIJK* and *adeFGH* also play an important role in the emergence of resistant *A.*  
66 *baumannii* strains [10].

67 The exact mode of transmission may not be known, because the isolation of *A. baumannii*  
68 strains in environmental surveillance cultures is not so frequent which makes eradication of

69 this organism very difficult in the hospital setting but it can be prevented by implementing  
70 good clinical practises and effective infection control measures [11–14]. Most of the studies  
71 consistently report on the nosocomial infection caused by *A. baumannii*. The hospital  
72 outbreaks and nosocomial infection by *A. baumannii* has been attributed to their increase  
73 antibiotic resistance, virulence and their ability to survive on inanimate and dry surface [4, 5,  
74 9, 10]. To understand more about the spread and epidemiology of *A. baumannii* in a  
75 hospital setting many molecular based methods have been employed. They can be broadly  
76 classified as 1) PCR-based DNA fingerprinting techniques (M13, ERIC, DAF4) 2) Restriction  
77 enzyme based (AFLP, RFLP and PFGE) 3) Sequence based (Single locus sequence based  
78 typing) 4) Single nucleotide polymorphism based on analyses of whole genome and 5) Multi  
79 locus sequence typing (MLST) [15]. The main aim of this study was to identify and track the  
80 circulating clonal types of *A. baumannii* in an Intensive care unit (ICU) setting to detect the  
81 mode of transmission between the patients in the months of June and November of 2015  
82 using molecular techniques such as MLST, SBT and DNA fingerprinting PCRs. This project  
83 also compares the efficacy of the molecular techniques based on cost, time and its effective  
84 usage in routine surveillance to identify circulating clonal types in hospital setting.

## 85 **Materials and Methods:**

### 86 **Bacterial isolates:**

87 *Acinetobacter baumannii* isolates were obtained from a tertiary care hospital, in South India,  
88 in June, 2015 (AB01-AB12) and November, 2015 (AB13 to AB 17) (Table S1). All isolates  
89 were from the same ICU setting and were either multidrug resistant (resistant to more than  
90 three classes of antibiotics) or extensively drug resistant (susceptible to two or less than two  
91 classes of antibiotics)[16]. The isolates were from blood and endotracheal aspirate (ETA). In

92 case of ETA isolates there were 3 inclusion criteria: The patient sample should have more  
93 than  $10^5$  CFU/ml of organisms, the pus cells should be moderate or more and radiological  
94 features must suggest ventilator associated pneumonia. Isolates which fulfilled at least two  
95 criteria were selected (Table S1). All the isolates were identified as *Acinetobacter*  
96 *baumannii* using PCR amplification of *bla*<sub>OXA-51-like</sub> gene and confirmed by sequencing of *rpoB*  
97 gene [17–19].

#### 98 **Antimicrobial Susceptibility Testing:**

99 Susceptibility pattern to different classes of antimicrobials were determined by standard  
100 disc diffusion method. The results were interpreted according to Clinical Laboratory  
101 Standard Institute guidelines [20, 21]. The antimicrobials used for disc diffusion  
102 susceptibility testing were ceftazidime (30 µg), cefepime (30 µg), piperacillin/tazobactam  
103 (100/10 µg), cefoperazone/sulbactam (75/30 µg), amikacin (30 µg), netilmicin (30 µg),  
104 tobramycin (10 µg), aztreonam (30µg), levofloxacin (5 µg), tetracycline (30 µg),  
105 trimethoprim/sulfamethoxazole (1.25/23.75 µg), imipenem (10 µg) and meropenem (10 µg).  
106 Minimum inhibitory concentration (MIC) by broth micro dilution (BMD) for polymyxin B and  
107 polymyxin E were performed for all clinical isolates of *A. baumannii* as per the CLSI  
108 guidelines. *A. baumannii* ATCC 19606 was used as the control strain.

#### 109 **CarbAcineto NP:**

110 CarbAcineto NP test was performed for the phenotypic assessment of carbapenemase  
111 activity for all *A. baumannii* strains [22]. The carbapenemase activity was detected by  
112 colour change from red to yellow, which results by the hydrolysis of imipenem leading to

113 decrease in pH value. Strains BAA-1705 (*bla*<sub>KPC</sub> positive) and BAA-1706 (carbapenemase  
114 negative) were included as positive and negative controls.

115 **PCR for the detection of carbapenemase genes:**

116 DNA extraction was performed using automated Qiagen QiaSymphony system as per the  
117 manufacturer's instructions [23]. Multiplex PCR for the detection of OXA classes of enzymes  
118 was performed as described earlier by Woodford et al [24]. A multiplex PCR was also  
119 performed to detect extended spectrum  $\beta$ -lactamases (ESBL) genes such as *bla*<sub>TEM</sub>, *bla*<sub>SHV</sub>,  
120 *bla*<sub>GES</sub>, *bla*<sub>PER</sub>, *bla*<sub>VEB</sub> and class A carbapenemase *bla*<sub>KPC</sub> and for the detection of *bla*<sub>IMP</sub>, *bla*<sub>VIM</sub>,  
121 *bla*<sub>SIM</sub>, *bla*<sub>NDM</sub>, and *bla*<sub>SPM</sub> metallo  $\beta$ -lactamases [25–28].

122 In order to detect allelic variants of genes, primers (Table S2) were designed using BioEdit  
123 (<http://www.mbio.ncsu.edu/BioEdit/page2.html>) and NCBI gene sequences. PCR was  
124 performed using Veriti thermal cycler, Applied Biosystem. The cycling conditions were:  
125 initial denaturation at 94 °C for 15 min, 35 cycles of 94 °C for 30 sec, 54 °C for 30 sec, 72 °C  
126 for 45 sec, followed by final extension at 72 °C for 10 min. The amplified products were  
127 sequenced using AB - Applied Biosystem 3130 - Genetic Analyser and then the sequence  
128 information was analysed and translated into amino acid sequences using BioEdit software.  
129 The translated information was used for blastp analysis using the Protein Basic Local  
130 Alignment Search Tool available through NCBI [29].

131 **Detection of insertion element associated with OXA51 and OXA23:**

132 To detect the presence of insertion sequence (IS) *ISAb<sub>a1</sub>*, PCR was first performed using  
133 primers described by Turton et al [30]. Also, mapping of *ISAb<sub>a1</sub>* element relative to *bla*<sub>OXA-23-</sub>  
134 like and *bla*<sub>OXA-51-like</sub> genes was accomplished. In case of *bla*<sub>OXA-23-like</sub>, forward primer of *ISAb<sub>a1</sub>*

135 with reverse of *bla*<sub>OXA-23-like</sub> and reverse of *ISAbal* with forward primer of *bla*<sub>OXA-23-like</sub> was  
136 used, while in *bla*<sub>OXA-51-like</sub>, FxOxa forward primer described by Lopes et al. (2011) and  
137 reverse of *bla*<sub>OXA-51-like</sub> were used (Table S2)[7, 24].

138 For mapping *bla*<sub>OXA-51-like</sub>, Qiagen Phusion high fidelity PCR master mix from New England Bio  
139 labs was used. The reaction mix consisted of 2 µl of template DNA, 10 µl of Phusion master  
140 mix, 1 µl each of forward and reverse primer (10 pM), 0.6 µl DMSO and 5.4 µl of molecular  
141 grade water. The cyclic conditions for *bla*<sub>OXA-51-like</sub> mapping were; initial denaturation at 95°C  
142 for 2 minutes, 35 cycles of 95°C for 10 secs, 57°C for 30 secs, 72°C for 30 secs, followed by  
143 final extension at 72°C for 10 minutes. For mapping of *ISAbal-bla*<sub>OXA-23-like</sub> Qiagen HotStart  
144 PCR master mix was used. The reaction mix consisted of 2 µl of template DNA, 10 µl of  
145 HotStart master mix, 1 µl each of forward and reverse primer (10 pM) and 6 µl of molecular  
146 grade water. The cycling conditions were; initial denaturation at 95°C for 15 minutes, 35  
147 cycles of 95°C for 30 secs, 56°C for 45 secs, 72°C for 1 minute followed by final extension at  
148 72°C for 10 minutes.

#### 149 **PCR for detection of virulence genes:**

150 PCR was performed to detect serine protease gene *pkf* and zinc-dependent metallo-  
151 endopeptidase genes *cpa1* and *cpa2* in this study (Table S2). The reaction mix consisted of 2  
152 µl of template DNA, 10 µl of Qiagen HotStart master mix, 1 µl each of forward and reverse  
153 primer (10pm) and 6 µl of molecular grade water. The cycling conditions for *pkf*, *cpa1* and  
154 *cpa2* were as follows: initial denaturation at 95°C for 15 minutes, 35 cycles of 95°C for 45  
155 secs, 52°C for 45 secs, 72°C for 2 minutes, followed by final extension at 72°C for 10  
156 minutes.

157 **Multilocus sequence typing:**

158 All *A. baumannii* isolates were subjected to MLST analysis using the Oxford scheme with  
159 primers and conditions described previously by Bartual et al [31]. The amplicons were  
160 purified using Magbio kit (Gaithersberg, US) and sequenced using the AB - Applied  
161 Biosystem 3130- Genetic Analyser. The sequences obtained were trimmed using FinchTV  
162 and BioEdit. After trimming the sequence were submitted in PubMLST data base and  
163 Sequence types (STs) were assigned. New STs and allele numbers were assigned by  
164 submitting the data to the curator of *A. baumannii* in MLST database. The clonal complexes  
165 (CCs) were established using the eBURST software (<http://eburst.mlst.net/>)[32].

166 **Single-locus sequence based typing:**

167 Another technique used for distinguishing *A. baumannii* is single-locus sequence based  
168 typing of *bla*<sub>OXA-51-like</sub> which is an intrinsic class D beta-lactamase gene in this species [33].  
169 The *bla*<sub>OXA-51-like</sub> variants were analysed using the Oxa 51F and Oxa 51R primers (Table S2).  
170 The cycling condition used were; Initial denaturation at 95°C for 15 minutes, 35 cycles of  
171 95°C for 1min, 50°C for 2min, 72°C for 3min, followed by final extension of 72°C for 10  
172 minutes. The amplicons were purified using Magbio kit and sequenced using the ABI-  
173 applied biosystem 3130- genetic analyser sequencing. The sequences obtained were  
174 trimmed and translated to their respective protein sequence using BioEdit. The translated  
175 sequence was blasted in NCBI using protein blast tool (blastp) to detect *bla*<sub>OXA-51-like</sub> variants.

176 **PCR based DNA fingerprinting:**

177 DNA fingerprinting analyses were performed using ERIC2, 5'-  
178 AAGTAAGTGACTGGGGTGAGCG-3', M13, 5'-GAGGGTGGCGTTCT-3' and DAF4, 5'-

179 CGGCAGCGCC-3' primers as described earlier [34]. Primers M13 and DAF4 target conserved  
180 sequences, while primer ERIC-2 targets enterobacterial repetitive sequences [34]. Slight  
181 modifications were done in the cycling condition to obtain optimal product amplification,  
182 initial denaturation was performed at 95°C for 15 mins, followed by 35 cycles of 95°C for 1  
183 min, 50°C for 2 mins, 72°C for 3mins, and final extension of 72°C for 10 mins for all three  
184 primer sets.

185

186 Cluster analysis was performed using the unweighted pair group method with mathematical  
187 averages, and relatedness was calculated using the band-based Dice coefficient with a 1.5%  
188 band tolerance and 1.5% optimisation setting for the whole profile using BIONUMERICS v7.6  
189 software (Applied Maths, Sint-Martens-Latem, Belgium). A value of 85% was chosen as the  
190 threshold for the establishment of clonal relatedness of the strains [35].

191

192

193 **Results:**

194 **Antimicrobial Susceptibility Testing:**

195 All isolates except AB17 were resistant to 7 classes of antimicrobials including; amikacin,  
196 aztreonam, ceftazidime, ciprofloxacin, imipenem, levofloxacin, meropenem, netilmicin,  
197 piperacillin/tazobactam, sulbactam, tobramycin, trimethoprim/ sulfamethoxazole. For  
198 carbapenem resistance the AST data was well supported by CarbAcineto NP which gave  
199 positive result for 94% (n=16) of the isolates. This test had 100% sensitivity (95%CI: 79.41%  
200 to 100.00%) and 100% specificity (2.50% to 100.00%). In case of colistin all isolates were  
201 susceptible, whereas for tigecycline and tetracycline the resistance was seen in 70% (n = 12)  
202 and 35% (n = 6) of isolates.

203 **Antimicrobial resistance genes:**

204 The intrinsic oxacillinase gene *bla*<sub>OXA-51-like</sub> was found in all 17 isolates of which 15 isolates  
205 were positive for *ISAbal-bla*<sub>OXA-23-like</sub> constituting a *Tn2008* while one isolate had *ISAbal-*  
206 *bla*<sub>OXA-23-like-ISAbal</sub> constituting a *Tn2006* transposon. The *bla*<sub>NDM-1</sub> metallo β-lactamases was  
207 detected in 23.5% (n=4) isolates, other genes such as *bla*<sub>KPC</sub>, *bla*<sub>IMP</sub>, *bla*<sub>VIM</sub>, *bla*<sub>SIM</sub>, *bla*<sub>SPM</sub>,  
208 *bla*<sub>OXA-24-like</sub> and *bla*<sub>OXA-58-like</sub> could not be detected. 35.2% of the isolates (n=6) were negative  
209 for tested ESBL encoding gene while *bla*<sub>PER-7</sub> was present in 58.8% of isolates (n=10) and  
210 *bla*<sub>TEM-1</sub> gene in 1 isolate (Table 1). The *bla*<sub>SHV</sub>, *bla*<sub>VEB</sub> and *bla*<sub>GES</sub> genes were not identified in  
211 any isolates. *ISAbal* element was present in all the isolates but in 94.1% of isolates (n=16),  
212 this element was found upstream of *bla*<sub>OXA-51-like</sub> gene (Table 1). Among the 17 isolates  
213 tested, 14 isolates (82.3%) were positive for proteinase kinase F (*pkf*) and one isolate  
214 positive for both *cpa1* and *cpa2* coagulation dependent metallo-endopeptidase (Table 1).

215 **Multilocus and Single-locus sequence based typing:**

216 Among the STs identified by MLST (Oxford scheme), five were novel and assigned as ST1305,  
217 ST1306, ST1307, ST1308 and ST1335 and were identified in five isolates. Other known  
218 strains, ST1114, ST391 and ST218 were detected in three isolates. ST848 strain was detected  
219 in 5 isolates in both June and November months, followed by ST862 identified in 2 isolates  
220 and ST195 in 2 isolates. (Table 1). The eBURST analyses of our strains with all identified STs  
221 in MLST database showed that ST195, ST218, ST848, ST1114, ST1305 belonged to CC92,  
222 whereas ST391 belonged to CC391 and ST862, ST1306, ST1308 belonged to CC862, whereas  
223 ST1307 and ST1335 were singletons (Figure 1). SBT was carried out for all 17 isolates of  
224 which 11 isolates carried the *bla*<sub>OXA-66</sub> variant, 3 isolates were *bla*<sub>OXA-104</sub> positive, 3 isolates  
225 were positive for one of the OXA-variant, *bla*<sub>OXA-68</sub>, *bla*<sub>OXA-144</sub> or *bla*<sub>OXA-343</sub>.

226 **PCR based DNA fingerprinting:**

227 Of the three different primer sets, M13 primer generated distinct fingerprint patterns, with  
228 only a relatively small number of secondary faint bands (Figure 2). All DNA fingerprinting  
229 methods generated at least 9 distinct clusters in which isolates could be grouped. Using the  
230 DAF4 primer seven isolates (cluster 1) grouped together of which five ST848 (CC92, OXA-66)  
231 isolates clustered together in the ERIC2 (cluster 4) and M13 (cluster 6) fingerprint profiles  
232 (Figure 2). The results obtained by MLST indicate that ST848 (n=5) isolates were isolated in  
233 the months of June (n=3) and November (n=2). It can be seen that ST848 isolates harbouring  
234 OXA-66 are clonal in nature as they clustered together in all of the three typing methods  
235 with 100% similarity pattern in case of DAF4 and M13 PCRs whereas 85% similarity in case  
236 of ERIC PCR. The timeframe indicates that this clone persisted over time from June as it was  
237 also observed in November. It can be said that ST862 isolates are different clones as one

238 strain has OXA-144 (AB12, June 2016) and the other has OXA-104 (Ab14, November 2016),  
239 further analyses using whole genome MLST can provide a better understanding on the  
240 evolution and stability of these strains. AB14 isolate was a ST862 strain whereas AB15 had  
241 ST1335 strain type. These two strains have differences in 3 housekeeping genes (Oxford  
242 MLST scheme) when compared to each other and M13 PCR rightly indicates that they are  
243 related but not identical to each other as opposed to DAF4 and ERIC PCR which cluster these  
244 two isolates at 100% similarity level. AB5 (ST218) and AB8 (ST195) had 1 allele difference at  
245 the MLST level and clustered well with DAF4 and ERIC PCR as opposed to M13 PCR. Similar  
246 clustering was also seen in the case of AB1 (ST1305) and AB3 (ST1306) but all 7 alleles were  
247 different and strains belonged to different clonal complexes. So different DNA fingerprinting  
248 techniques can often give different results which need to be supplemented with other  
249 genotypic and sequence based data for understanding the spread and persistence of clones  
250 in hospital settings.

251

252 **Discussion:**

253 Restriction and hybridisation based techniques like ribotyping and Pulsed-Field Gel  
254 electrophoresis (PFGE) though have moderate – high relative discriminatory power, relative  
255 reproducibility and repeatability; they are laborious and more time consuming not so cost  
256 effective for routine surveillance in low income countries and requires special technical skills  
257 such as DNA plug preparation and handling [15]. Multi-locus sequence typing (MLST) has a  
258 high discriminatory power whereas Next generation sequencing (NGS) has a very high  
259 discriminatory power but as these techniques involve multiple steps such as PCRs of  
260 housekeeping gene and sequencing in case of MLST and library preps, genome assemblies  
261 for NGS. MLST is a good epidemiological tool for global tracking of clones as opposed to  
262 PFGE which is reliably detects hospital outbreaks and is useful in strain tracking related to  
263 persistent hospital clones [31].

264 In a recent study, wgMLST (whole genome Multi Locus Sequence Typing) was regarded as  
265 the best approach for real-time surveillance as it delivers optimal resolution and  
266 epidemiological concordance while providing unambiguous nomenclature [36]. The Single  
267 locus based typing (SBT) which involves amplifying and sequencing *bla*<sub>OXA-51-like</sub> gene of *A.*  
268 *baumannii* provides some advantage over MLST as it involves amplification and sequencing  
269 of just one gene as opposed to seven and is said to distinguish all epidemic and sporadic  
270 lineages of *A. baumannii* strains on par with MLST. Based on the findings of Pournaras *et al*  
271 [33], SBT should correlate well with MLST but in our study it gave discrepant results where  
272 *bla*<sub>OXA-66</sub> (AB03), *bla*<sub>OXA-104</sub> (AB14) and *bla*<sub>OXA-144</sub> (AB12) clustered in a single clonal complex  
273 862 (Table 1) and hence using SBT data alone can often lead to misinterpretation of the  
274 results in order to distinguishing clones of *A. baumannii*. The clonal complex of strains in

275 comparison to the *bla*<sub>OXA-51-like</sub> variants showed good correlation. Hence, it can be said that  
276 SBT can give some information about the clone type and its association with Global Clones  
277 1-8 but this has to be supplemented with other methods such as M13 PCR, PFGE, MLST or  
278 whole genome MLST to reliably interpret the results.

279 Typing methods such as Rapid Amplified Polymorphic DNA (RAPD) typing (using M13, DAF4  
280 primers) and repetitive extragenic palindrome (rep) PCR typing are simple and easy to  
281 perform and can provide an effective alternative in understanding the epidemiology of  
282 strains in resource limited countries as on most occasions they are reliable, less  
283 complicated, rapid and cost effective [37]. Although it can have some disadvantages such as  
284 low reproducibility between the labs but this can be standardised for usage within the same  
285 lab [15]. With the three DNA fingerprinting methods such as M13, ERIC-2 and DAF4, we  
286 observed that each technique produced a unique DNA fingerprint but M13 PCR was slightly  
287 more reproducible with distinct bands than others and had a higher discriminatory power  
288 than ERIC-2 and DAF-4 PCR techniques. Though the reproducibility of M13 technique may  
289 be quiet low between laboratories due to several factors such as standardisation of  
290 template concentration, use of PCR kits or enzymes used in reaction, thermocyclers and PCR  
291 conditions [38], but within a single setting it can prove to effective in detecting persistent  
292 clones that are may be difficult to detect in routine environmental surveillance where  
293 environmental surveillance fails in detection of clones [34]. We also observed that M13 PCR  
294 also had a higher discriminatory power than MLST and SBT (Figure 2), but small sample size  
295 and using MLST as the gold standard was a limitation of our study. It has also been shown  
296 previously that rep-PCR (ERIC) may prove to be less discriminatory between strains as a  
297 result of repeated independent DNA preparations or DNA quality [39]. MLST data showed

298 that isolates belonging to Global clone 2 (GC2) (CC92 -Oxford scheme) found to occur in  
299 Asian countries and also in the Tamil Nadu region of South India was also the most  
300 prevalent clone in our study [40, 41]. On the contrary Global clone 1 (GC1) which  
301 corresponds to CC108 and found to be more prevalent in India was not observed in our  
302 study [40, 41].

303 The secondary finding of our study was detection of carbapenem resistance in *A. baumannii*.  
304 Previous studies on ESBLs have demonstrated, *bla*<sub>PER</sub> was common and *bla*<sub>TEM</sub> was rarely  
305 detected in *A. baumannii* [42, 43]. Similarly, in this study, *bla*<sub>PER-7</sub> was detected in 10  
306 isolates, whereas *bla*<sub>TEM-1</sub> was found in only one isolate. It is indeed possible that the *bla*<sub>PER-7</sub>  
307 gene could have been plasmid associated as observed by Opazo *et al* but this was not tested  
308 in the present study [43]. Pathogens that produce carbapenemase along with ESBL can be  
309 particularly challenging for clinicians to treat, since they are resistant to antibiotics of  
310 different classes [25]. In the present study, most of the isolates were positive for *ISAbal1* and  
311 this element was also detected upstream of the *bla*<sub>OXA-51-like</sub> and *bla*<sub>OXA-23-like</sub> genes which  
312 suggests that carbapenem resistance may be due to the overexpression of *bla*<sub>OXA-51-like</sub> and  
313 *bla*<sub>OXA-23-like</sub> genes [30]. In one isolate (AB03, ST1306 isolated from blood and ETA of the  
314 same patient), the *bla*<sub>OXA-23-like</sub> was bracketed by two copies of *ISAbal1* forming a composite  
315 transposon (Tn2006) which has the potential to mobilise OXA-23 gene in different strains of  
316 *A. baumannii* [44]. Tn2006 occurring in different genotypic variants of *A. baumannii* is often  
317 associated with higher mortality [45] and this was true in the case of this patient who  
318 succumbed to his injuries during the course of this study.

319 The once predominant dogma that described antibiotic resistance and fitness as an inverse  
320 relationship may not hold true for Gram negative bacteria such as *Pseudomonas* where

321 increased virulence is associated with increased resistance to polymyxin B, gentamicin and  
322 ciprofloxacin as a result of swarming motility but this dogma holds true for bacteria such as  
323 *A. baumannii* [46]. The *cpa* gene known for degrading the coagulation factors like Factor V  
324 and fibrinogen, thus interfering with contact-activated clot formation in human plasma, a  
325 process which is required for effective innate immune defence during *A. baumannii*  
326 infection was observed in one isolate in our study [9]. By this disruption of the common  
327 pathway of coagulation the bacterial pathogens can promote bleeding and dissemination  
328 during infection in debilitated patients. Most of our isolates were positive for *pkf*, a serine  
329 protease responsible for degrading essential complement compounds such as C3 and  
330 complement regulators like properdin contributing to serum resistance and reduce biofilm  
331 formation, possibly by preventing steps involved in initial attachment. PKF plays an  
332 important role in *A. baumannii* serum resistance by the cleavage of complement  
333 components, leading to the dissociation of the cascade and subsequent survival of the  
334 bacterium [8]. *A. baumannii* shows pathology most often to patients who are severely  
335 immunocompromised, thus inactivation of the complement immune defence could allow an  
336 onset of fulminating infection. Proteases cleave proteins involved in cell-to-cell adhesion,  
337 which often results in dispersal of bacteria from a biofilm [47]. *A. baumannii* may be able to  
338 regulate its behaviour in a host by forming biofilm during optimal conditions or by producing  
339 PKF to inhibit biofilm formation when it would be advantageous for it to spread at different  
340 sites.

341

342 **Conclusions:**

343 We have compelling evidence that most of the *A. baumannii* infections are hospital acquired  
344 especially in the ICU setting as evidenced by other studies. Due to the stringent sterilization  
345 protocols most of the clones can be eradicated, but few persistent ones remain. Although  
346 our sample size is quite low (n=17), and a single centre experience study from a single  
347 department, it shows that M13 PCR is a cost effective technique which proves to be useful for  
348 identification of clones and is slightly better than the DAF or ERIC PCR fingerprinting and  
349 standardising this method can offer an alternative and a reliable way for strain tracking in a  
350 routine lab environment which can help in prevention of further nosocomial outbreaks.  
351 Fingerprinting analyses along with MLST or indeed whole genome MLST can further aid in  
352 long term surveillance and in understanding bacterial strain evolution. Strict preventive  
353 measures that reduce transmissibility of strains, along with routine surveillance practices,  
354 can help decreasing patient morbidity and mortality and in improving antibiotic policies in  
355 the hospital which in turn can slower the evolution of more resistant organisms.

356

357 **Acknowledgement**

358 The authors gratefully acknowledge Indian Council of Medical Research (ICMR), New Delhi,  
359 for providing the fund for this research (ref. no. AMR/TF/54/13ECDHII dated 23/10/2013)  
360 and the Institutional Review Board of the Christian Medical College, Vellore (83-i/11/13).

361 **Author Disclosure Statement**

362 No competing financial interests exist.

363 **Reference:**

- 364 1. **Howard A, O'Donoghue M, Feeney A, Sleator RD.** Acinetobacter baumannii: an  
365 emerging opportunistic pathogen. *Virulence* 2012;3:243–50.
- 366 2. **Custovic A, Smajlovic J, Tihic N, Hadzic S, Ahmetagic S, et al.** Epidemiological  
367 Monitoring of Nosocomial Infections Caused by Acinetobacter Baumannii. *Med Arh*  
368 2014;68:402–406.
- 369 3. **Cisneros JM, Rodríguez-Baño J.** Nosocomial bacteremia due to Acinetobacter  
370 baumannii: epidemiology, clinical features and treatment. *Clin Microbiol Infect*  
371 2002;8:687–693.
- 372 4. **Ellis D, Cohen B, Liu J, Larson E.** Risk factors for hospital-acquired antimicrobial-  
373 resistant infection caused by Acinetobacter baumannii. *Antimicrob Resist Infect*  
374 *Control* 2015;4:40.
- 375 5. **Wisplinghoff H, Edmond MB, Pfaller M a, Jones RN, Wenzel RP, et al.** Nosocomial  
376 bloodstream infections caused by Acinetobacter species in United States hospitals:  
377 clinical features, molecular epidemiology, and antimicrobial susceptibility. *Clin Infect*  
378 *Dis* 2000;31:690–697.
- 379 6. **Lowings M, Ehlers MM, Dreyer AW, Kock MM.** High prevalence of oxacillinases in  
380 clinical multidrug-resistant Acinetobacter baumannii isolates from the Tshwane  
381 region, South Africa - an update. *BMC Infect Dis* 2015;15:521.
- 382 7. **Lopes BS, Evans BA, Amyes SGB.** Disruption of the blaOXA-51-like gene by ISAba16  
383 and activation of the blaOXA-58 gene leading to carbapenem resistance in  
384 acinetobacter baumannii Ab244. *J Antimicrob Chemother* 2012;67:59–63.

- 385 8. **King LB, Pangburn MK, McDaniel LS.** Serine protease PKF of *Acinetobacter baumannii*  
386 results in serum resistance and suppression of biofilm formation. *J Infect Dis*  
387 2013;207:1128–1134.
- 388 9. **Tilley D, Law R, Warren S, Samis JA, Kumar A.** CpaA a novel protease from  
389 *Acinetobacter baumannii* clinical isolates deregulates blood coagulation. *FEMS*  
390 *Microbiol Lett* 2014;356:53–61.
- 391 10. **Coyne S, Courvalin P, Périchon B.** Efflux-mediated antibiotic resistance in  
392 *Acinetobacter* spp. *Antimicrob Agents Chemother* 2011;55:947–953.
- 393 11. **Corbella X, Pujol M, Argerich MJ, Ayats J, Sendra M, Peña C AJ.** Environmental  
394 Sampling of *Acinetobacter baumannii*: Moistened Swabs Versus Moistened Sterile  
395 Gauze Pads. *Infect Control Hosp Epidemiol* 1999;20:458–60.
- 396 12. **Tsiatsiou O, Iosifidis E, Katragkou A, Dimou V, Sarafidis K, et al.** Successful  
397 management of an outbreak due to carbapenem-resistant *Acinetobacter baumannii*  
398 in a neonatal intensive care unit. *Eur J Pediatr* 2015;174:65–74.
- 399 13. **Shannon RP.** Eliminating hospital acquired infections: is it possible? Is it sustainable?  
400 Is it worth it? *Trans Am Clin Climatol Assoc* 2010;122:103–114.
- 401 14. **Inweregbu K.** Nosocomial infections. *Contin Educ Anaesthesia, Crit Care Pain*  
402 2005;5:14–17.
- 403 15. **Foxman B, Zhang L, Koopman JS, Manning SD, Marrs CF.** Choosing an appropriate  
404 bacterial typing technique for epidemiologic studies. *Epidemiol Perspect Innov*  
405 2005;2:10.
- 406 16. **Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al.** Multidrug-

- 407 resistant, extensively drug-resistant and pandrug-resistant bacteria: An international  
408 expert proposal for interim standard definitions for acquired resistance. *Clin*  
409 *Microbiol Infect* 2012;18:268–281.
- 410 17. **Scola B La, Gundi V a KB, Khamis A, Raoult D.** The principles of DNA Sequencing.  
411 *Society* 2006;44:827–832.
- 412 18. **Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, et al.** Identification of  
413 *Acinetobacter baumannii* by Detection of the bla OXA-51-like Carbapenemase Gene  
414 Intrinsic to This Species. 2006;44:2974–2976.
- 415 19. **Zander E, Higgins PG, Fernández-González A, Seifert H.** Detection of intrinsic blaOXA-  
416 51-like by multiplex PCR on its own is not reliable for the identification of  
417 *Acinetobacter baumannii*. *Int J Med Microbiol* 2013;303:88–89.
- 418 20. **CLSI M100-S21.** *Performance Standards for Antimicrobial Susceptibility Testing;*  
419 *Twenty-First Informational Supplement. CLSI document M100-S21.* 2012.
- 420 21. **Franklin R. Cockerill, III M, Jean B. Patel, PhD D.** M100-S25 Performance Standards  
421 for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. *Clin*  
422 *Lab Stand Inst* 2015;44–49.
- 423 22. **Dortet L, Poirel L, Errera C, Nordmann P.** CarbAcineto NP test for rapid detection of  
424 carbapenemase- producing *Acinetobacter* spp. *J Clin Microbiol* 2014;52:2359–2364.
- 425 23. **QIAGEN Group.** QIASymphony DNA Handbook.
- 426 24. **Woodforda N, Ellingtona MJ, Coelho JM, Turtonb JF, Warda ME, Brownc S, Amyes**  
427 **SGB.** Multiplex PCR for genes encoding prevalent OXA carbapenemases in  
428 *Acinetobacter* spp. *Int J Antimicrob Agents* 2006;27:351–3.

- 429 25. **Lascols C, Hackel M, Marshall SH, Hujer AM, Bouchillon S, et al.** Increasing  
430 prevalence and dissemination of NDM-1 metallo- $\beta$ -lactamase in India: Data from the  
431 SMART study (2009). *J Antimicrob Chemother* 2011;66:1992–1997.
- 432 26. **Dallenne C, da Costa A, Decré D, Favier C, Arlet G.** Development of a set of multiplex  
433 PCR assays for the detection of genes encoding important  $\beta$ -lactamases in  
434 Enterobacteriaceae. *J Antimicrob Chemother* 2010;65:490–495.
- 435 27. **Poirel L, Walsh TR, Cuvillier V, Nordmann P.** Multiplex PCR for detection of acquired  
436 carbapenemase genes. *Diagn Microbiol Infect Dis* 2011;70:119–123.
- 437 28. **Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, et al.** Novel  
438 carbapenem-hydrolyzing  $\beta$ -lactamase, KPC-1, from a carbapenem-resistant strain of  
439 *Klebsiella pneumoniae*. *Antimicrob Agents Chemother* 2001;45:1151–1161.
- 440 29. **Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ.** Basic local alignment search  
441 tool. *J Mol Biol* 1990;215:403–10.
- 442 30. **Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, et al.** The role of ISAbal in  
443 expression of OXA carbapenemase genes in *Acinetobacter baumannii*. *FEMS*  
444 *Microbiol Lett* 2006;258:72–77.
- 445 31. **Bartual SG, Seifert H, Hippler C, Rodríguez-valera F, Domí MA.** Development of a  
446 Multilocus Sequence Typing Scheme for Characterization of Clinical Isolates of  
447 *Acinetobacter baumannii* Development of a Multilocus Sequence Typing Scheme for  
448 Characterization of Clinical Isolates of *Acinetobacter baumannii*. *J Clin Microbiol*  
449 2005;43:4382–4390.
- 450 32. **Feil EJ.** eBURSTV3 Manual. 2006;1–23.

- 451 33. **Pournaras S, Gogou V, Giannouli M, Dimitroulia E, Dafopoulou K, et al.** Single-locus-  
452 sequence-based typing of blaOXA-51-like genes for rapid assignment of Acinetobacter  
453 baumannii clinical isolates to international clonal lineages. *J Clin Microbiol*  
454 2014;52:1653–1657.
- 455 34. **Grundmann HJ, Towner KJ, Dijkshoorn L, Seifert H, Vaneechoutte M.** Multicenter  
456 study using standardized protocols and reagents for evaluation of reproducibility of  
457 PCR-based fingerprinting of Acinetobacter spp . Multicenter Study Using Standardized  
458 Protocols and Reagents for Evaluation of Reproducibility of PCR-Based Fin.  
459 1997;35:3071–3077.
- 460 35. **Lopes BS, Al-Agamy MH, Ismail MA, Shibl AM, Al-Qahtani AA, et al.** The  
461 transferability of blaOXA-23 gene in multidrug-resistant Acinetobacter baumannii  
462 isolates from Saudi Arabia and Egypt. *Int J Med Microbiol* 2015;305:581–588.
- 463 36. **Nadon C, Walle I Van, Gerner-smidt P, Campos J, Chinen I, et al.** PulseNet  
464 International : Vision for the implementation of whole genome sequencing ( WGS )  
465 for global food- borne disease surveillance. 1–12.
- 466 37. **Jonas D, Spitzmüller B, Weist K, Rüden H, Daschner FD.** Comparison of PCR-based  
467 methods for typing Escherichia coli. *Clin Microbiol Infect* 2003;9:823–831.
- 468 38. **Tyler KD, Wang G, Tyler SD, Johnson WM.** GUEST COMMENTARY Factors Affecting  
469 Reliability and Reproducibility of Amplification-Based DNA Fingerprinting of  
470 Representative Bacterial Pathogens. *J Clin Microbiol* 1997;35:339–346.
- 471 39. **Prodelalová J, Spanová a, Rittich B.** Application of PCR, rep-PCR and RAPD  
472 techniques for typing of Lactococcus lactis strains. *Folia Microbiol (Praha)*  
473 2005;50:150–154.

- 474 40. **Saranathan R, Vasanth V, Vasanth T, Shabareesh PRV, Shashikala P, et al.**  
475 Emergence of carbapenem non-susceptible multidrug resistant *Acinetobacter*  
476 *baumannii* strains of clonal complexes 103<sup>B</sup> and 92<sup>B</sup> harboring OXA-type  
477 carbapenemases and metallo- $\beta$ -lactamases in Southern India. *Microbiol Immunol*  
478 2015;59:277–284.
- 479 41. **Kim DH, Choi J, Kim W, Kim H, Chung R, et al.** Spread of Carbapenem-Resistant  
480 *Acinetobacter baumannii* Global Clone 2 in Asia and AbaR-Type Resistance Islands.  
481 2013;57:5239–5246.
- 482 42. **Potron A, Poirel L, Nordmann P.** Emerging broad-spectrum resistance in  
483 *Pseudomonas aeruginosa* and *Acinetobacter baumannii*: Mechanisms and  
484 epidemiology. *Int J Antimicrob Agents* 2015;45:568–585.
- 485 43. **Opazo A, Sonnevend A, Lopes B, Hamouda A, Ghazawi A, et al.** Plasmid-encoded  
486 PER-7  $\beta$ -lactamase responsible for ceftazidime resistance in *Acinetobacter baumannii*  
487 isolated in the United Arab Emirates. *Journal of Antimicrobial Chemotherapy*  
488 2012;67:1619–1622.
- 489 44. **Mugnier PD, Poirel L, Nordmann P.** Functional analysis of insertion sequence ISAba1,  
490 responsible for genomic plasticity of *Acinetobacter baumannii*. *J Bacteriol*  
491 2009;191:2414–2418.
- 492 45. **Lee H, Chang R, Su L, Liu S, Wu S, et al.** International Journal of Antimicrobial Agents  
493 Wide spread of Tn 2006 in an AbaR4-type resistance island among carbapenem-  
494 resistant *Acinetobacter baumannii* clinical isolates in Taiwan. *Int J Antimicrob Agents*  
495 2012;40:163–167.
- 496 46. **Beceiro A, Tomás M, Bou G.** Antimicrobial resistance and virulence: A successful or

497 deleterious association in the bacterial world? *Clin Microbiol Rev* 2013;26:185–230.

498 47. **Karatan E, Watnick P.** Signals, regulatory networks, and materials that build and

499 break bacterial biofilms. *Microbiol Mol Biol Rev* 2009;73:310–347.

500

501

502

503

504

505

506

507

508

509 **Figure Legends**

510 **Figure 1:** eBURST analysis for *Acinetobacter baumannii* obtained by comparing database STs  
511 against the studied STs (2017-08-16).

512

513 **Figure 2:** DNA finger printing pattern obtained - using a) DAF4, b) ERIC 2 and c) M13 primer;  
514 Lane 1-17 represents isolate AB01 to AB17 respectively.

515